Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

ALINA A GOVER

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1861449977
CMS profile
416053
Location
WILMINGTON, DE

General Payments · PY2018–2024

$3,957.35

  • Reported across 230 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$1,022.52

33 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,022.52 33

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $210.36 8
Acerta Pharma LLC $195.06 3
Astellas Pharma US Inc $173.07 6
ITI, Inc. $141.53 2
KVK-Tech, Inc. $71.76 1
Indivior Inc. $56.60 3
ABBVIE INC. $54.32 3
Otsuka America Pharmaceutical, Inc. $39.38 2
Braeburn Inc. $33.24 2
Lilly USA, LLC $17.29 1
Evofem Biosciences, Inc. $16.06 1
Phathom Pharmaceuticals, Inc. $13.85 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $739.75 59
PY2019 $935.23 52
PY2020 $289.94 20
PY2021 $351.66 26
PY2022 $328.74 20
PY2023 $289.51 20
PY2024 $1,022.52 33

Payment records · PY2024 (33)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
ABBVIE INC. $18.39 01/25/2024 Food and Beverage Undisputed 01/23/2026 1103825614 CMS
ABBVIE INC. $20.81 04/05/2024 Food and Beverage Undisputed 01/23/2026 1103825616 CMS
ABBVIE INC. $15.12 05/15/2024 Food and Beverage Undisputed 01/23/2026 1103825618 CMS
Astellas Pharma US Inc $9.33 02/08/2024 Food and Beverage Undisputed 01/23/2026 1139314134 CMS
Astellas Pharma US Inc $124.99 05/09/2024 Food and Beverage Undisputed 01/23/2026 1139379874 CMS
Astellas Pharma US Inc $15.00 05/16/2024 Food and Beverage Undisputed 01/23/2026 1139361497 CMS
Astellas Pharma US Inc $4.65 09/20/2024 Food and Beverage Undisputed 01/23/2026 1139395601 CMS
Astellas Pharma US Inc $3.69 09/20/2024 Food and Beverage Undisputed 01/23/2026 1139395643 CMS
Astellas Pharma US Inc $15.41 11/14/2024 Food and Beverage Undisputed 01/23/2026 1139435466 CMS
AstraZeneca Pharmaceuticals LP $50.91 03/18/2024 Food and Beverage Undisputed 01/23/2026 1105848836 CMS
AstraZeneca Pharmaceuticals LP $26.97 05/03/2024 Food and Beverage Undisputed 01/23/2026 1104614234 CMS
AstraZeneca Pharmaceuticals LP $117.18 06/05/2024 Food and Beverage Undisputed 01/23/2026 1104360041 CMS
Braeburn Inc. $17.15 02/22/2024 Food and Beverage Undisputed 01/23/2026 1125598757 CMS
Braeburn Inc. $16.09 03/29/2024 Food and Beverage Undisputed 01/23/2026 1125598755 CMS
Evofem Biosciences, Inc. $16.06 06/21/2024 Food and Beverage Undisputed 01/23/2026 1091273464 CMS
GlaxoSmithKline, LLC. $18.67 03/29/2024 Food and Beverage Undisputed 01/23/2026 1116365261 CMS
GlaxoSmithKline, LLC. $10.36 04/25/2024 Food and Beverage Undisputed 01/23/2026 1116172325 CMS
GlaxoSmithKline, LLC. $15.81 05/07/2024 Food and Beverage Undisputed 01/23/2026 1115936255 CMS
GlaxoSmithKline, LLC. $11.41 05/23/2024 Food and Beverage Undisputed 01/23/2026 1116494492 CMS
GlaxoSmithKline, LLC. $10.35 08/29/2024 Food and Beverage Undisputed 01/23/2026 1116421277 CMS
GlaxoSmithKline, LLC. $9.95 10/24/2024 Food and Beverage Undisputed 01/23/2026 1116488071 CMS
GlaxoSmithKline, LLC. $125.00 10/29/2024 Food and Beverage Undisputed 01/23/2026 1116485531 CMS
GlaxoSmithKline, LLC. $8.81 11/21/2024 Food and Beverage Undisputed 01/23/2026 1116240736 CMS
Indivior Inc. $18.68 10/09/2024 Food and Beverage Undisputed 01/23/2026 1144528856 CMS
Indivior Inc. $17.61 10/29/2024 Food and Beverage Undisputed 01/23/2026 1144528858 CMS
Indivior Inc. $20.31 12/05/2024 Food and Beverage Undisputed 01/23/2026 1144528860 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $11.53 11/04/2024 Food and Beverage Undisputed 01/23/2026 1143233503 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $130.00 11/14/2024 Food and Beverage Undisputed 01/23/2026 1143233506 CMS
KVK-Tech, Inc. $71.76 12/18/2024 Food and Beverage Undisputed 01/23/2026 1063917256 CMS
Lilly USA, LLC $17.29 01/12/2024 Food and Beverage Undisputed 01/23/2026 1135996896 CMS
Otsuka America Pharmaceutical, Inc. $22.25 02/15/2024 Food and Beverage Undisputed 01/23/2026 1118900128 CMS
Otsuka America Pharmaceutical, Inc. $17.13 04/01/2024 Food and Beverage Undisputed 01/23/2026 1118900130 CMS
Phathom Pharmaceuticals, Inc. $13.85 07/18/2024 Food and Beverage Undisputed 01/23/2026 1151067375 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.